Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis

European Scientific Journal ESJ
doi 10.19044/esj.2019.v15n15p268
Full Text
Abstract

Available in full text

Date
Authors
Publisher

European Scientific Institute, ESI

Related search

Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes

Therapeutics and Clinical Risk Management
2018English

Euglycemic Diabetic Ketoacidosis Induced by Empagliflozin, Sodium-Glucose Cotransporter-2 Inhibitor, in Patient With Diabetes Mellitus Type 2 After Thoracic Surgery

Lijecnicki Vjesnik
Medicine
2020English

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin

Journal of Investigative Medicine High Impact Case Reports
RiskEpidemiologyReliabilitySafetySafety ResearchQuality
2017English

Relationship Between Euglycemic Diabetic Ketoacidosis and SGLT-2 Inhibitors

Global Journal of Endocrinological Metabolism
2018English

The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis

2018English

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Increased Grip Strength With Sodium-Glucose Cotransporter 2

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2016English

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy